Quotient Clinical
Ruddington, NG11 6JS, United Kingdom
NCT Number: NCT03107013
This is a single-centre, open-label, non-randomised, single oral dose study in healthy male subjects to assess the mass balance recovery of carbon-14 (14C)-BTD-001.
Looking for future studies?
Notify Me30 year–65 year
Male
Interventional
Phase 1
Ruddington, NG11 6JS, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Carbon-14 labeled BTD-001
Time frame: Maximum 12 days
The percentage of radioactive dose of [14C] radiolabelled BTD-001 recovered in urine, faeces, and plasma
Time frame: Maximum 12 days
To provide plasma, urine and faecal samples for metabolite profiling and structural identification
Time frame: Maximum 12 days
[14C]-BTD-001 metabolite profiling and structural identification in plasma, urine and faeces
Time frame: Maximum 12 days
Identification of the chemical structure of each metabolite accounting for more than 10% (by AUC) of circulating total radioactivity
Time frame: Maximum 12 days
To evaluate the extent of distribution of total radioactivity into blood cells
Time frame: Maximum 12 days
Safety and tolerability of BTD-001 by assessing physical examination
Time frame: Maximum 12 days
Safety and tolerability of BTD-001 by assessingsafety laboratory tests and AEs
Time frame: Maximum 12 days
Safety and tolerability of BTD-001 by assessing vital signs
Time frame: Maximum 12 days
Safety and tolerability of BTD-001 by assessing ECGs
Time frame: Maximum 12 days
Safety and tolerability of BTD-001 by assessing physical examination AEs
Time frame: Maximum 12 days
Maximum Observed Plasma Concentration
Time frame: Maximum 12 days
time to reach maximum concentration
Time frame: Maximum 12 days
elimination half-life
Balance Therapeutics
Industry
An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BTD-001 in Healthy Male Subjects
Acronym: HV103
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03646292
Diabetes Mellitus, Diabetes Mellitus, Type 2
Seoul, South Korea
View Trial DetailsNCT05657860
Aberrant Motor Behavior in Dementia, Abnormalities, Multiple
Brooklyn, New York, United States
View Trial DetailsNCT04518852
Adenocarcinoma, Antineoplastic Agents
Chengdu, Sichuan, China
View Trial DetailsNCT05321602
Antipsychotic Agents, Central Nervous System Depression
Little Rock, Arkansas, United States
View Trial Details